Taysha Gene Therapies (TSHA) FCF Margin: 2022-2025
Historic FCF Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to 161,620.00%.
- Taysha Gene Therapies' FCF Margin rose 16282503.00% to 161,620.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,352.85%, marking a year-over-year decrease of 55177.00%. This contributed to the annual value of -979.23% for FY2024, which is 48161.00% down from last year.
- Per Taysha Gene Therapies' latest filing, its FCF Margin stood at 161,620.00% for Q3 2025, which was up 15,704.15% from -1,035.75% recorded in Q2 2025.
- Taysha Gene Therapies' FCF Margin's 5-year high stood at 161,620.00% during Q3 2025, with a 5-year trough of -1,961.24% in Q2 2024.
- Moreover, its 3-year median value for FCF Margin was -781.59% (2023), whereas its average is 13,895.57%.
- In the last 5 years, Taysha Gene Therapies' FCF Margin plummeted by 785,792bps in 2023 and then skyrocketed by 16,282,503bps in 2025.
- Over the past 4 years, Taysha Gene Therapies' FCF Margin (Quarterly) stood at -950.42% in 2022, then spiked by 50,275bps to -447.67% in 2023, then plummeted by 45,767bps to -905.34% in 2024, then surged by 16,282,503bps to 161,620.00% in 2025.
- Its FCF Margin stands at 161,620.00% for Q3 2025, versus -1,035.75% for Q2 2025 and -957.56% for Q1 2025.